1. Is Shared Decision Making in Prostate Cancer Restrained by Evidence-Based Medicine? 
Jacques Irani 
European Urology Supplements 
Volume 9, Issue 11, Pages (December 2010)
DOI: /j.eursup
Copyright © 2010 European Association of Urology Terms and Conditions

2. Fig. 1
Incidence of biopsy-detected prostate cancer in the Prostate Cancer Prevention Trial (PCPT) study at 7 yr and the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study at 4 yr; relative risk reduction (RR) indicated [10,11].
European Urology Supplements 2010 9, DOI: ( /j.eursup )
Copyright © 2010 European Association of Urology Terms and Conditions

3. Fig. 2
Point incidence of prostate cancer at 12 mo in patients with high-grade prostatic intraepithelial neoplasia treated daily with 20, 40, or 60mg toremifene or placebo. Significant reduction with the 20-mg dose compared with placebo (p=0.045). Reproduced with permission from Price et al [15].
European Urology Supplements 2010 9, DOI: ( /j.eursup )
Copyright © 2010 European Association of Urology Terms and Conditions

4. Fig. 3
Overall survival in patients with T3/4 M0 or M1 prostate cancer treated with androgen-deprivation therapy on an intermittent or continuous basis. The number of patients still in active follow-up is indicated. Reproduced with the permission from Calais da Silva et al [31].
European Urology Supplements 2010 9, DOI: ( /j.eursup )
Copyright © 2010 European Association of Urology Terms and Conditions

5. Fig. 4
Outcome of a patient questionnaire on the preferred type of decision making in men with prostate cancer (n=100) Reproduced with permission from Wong et al [34].
European Urology Supplements 2010 9, DOI: ( /j.eursup )
Copyright © 2010 European Association of Urology Terms and Conditions